Pitfalls of Using Home Sleep Testing for Diagnosing Obstructive Sleep Apnea and Narcolepsy

Pitfalls of Using Home Sleep Testing for Diagnosing Obstructive Sleep Apnea and Narcolepsy

On-Demand Webcast

Meir Kryger, MD, FRCPC
Professor of Medicine
Yale School of Medicine
New Haven, CT

Steven Plenzler, PhD, D, ABSM
Solution Lead, Sleep Management Program
eviCore Healthcare
Bluffton, SC

Russell Rosenberg, PhD, D, ABSM
Founder, Atlanta Progressive CME
Atlanta, GA

Intended Learners

Clinicians and case managers working in managed care, primary care physicians, sleep specialists, neurologists, psychiatrists, advanced practice nurses and physician assistants.

Learning Objectives
Upon completion of this activity, participants should be able to:
  • Evaluate limitations of current home sleep testing for diagnosing narcolepsy.
  • Compare advantages and disadvantages of using home sleep testing as an initial objective diagnostic test for hypersomnolence and develop strategies for comprehensive testing.
  • Determine which sleep complaints and symptoms are indicative of a hypersomnolence disorder other than obstructive apnea that warrants in-lab polysomnography with a multiple sleep latency test.  
Activity Overview

This CME activity will examine the role of Home Sleep Testing (HST) in evaluating patients with suspected obstructive sleep apnea and/or narcolepsy.  The 60-minute program will illustrate the capabilities and limitations of HST, so that clinicians can order appropriate testing based on efforts to determine the existence of single or multiple sleep disorders.  The program features the expertise of key opinion leaders in the areas of managed care, pulmonology and sleep medicine.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring webcast.

Release date: June 29, 2018
Expiration date: June 29, 2019
Estimated time to complete: 1 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


  This activity has been planned and implemented by North American Center for Continuing Medical Education, LLC (NACCME) and Atlanta Progressive CME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Atlanta Progressive CME (APCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Atlanta Progressive CME designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is the policy of Atlanta Progressive CME to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME’s) Standards for Commercial Support, all planners, teachers, authors, content providers and content reviewers involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. An individual has a relevant financial relationship if he or she (or spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. A commercial interest, as defined by the ACCME, is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.


This activity is approved for 1.0 contact hour (.1 CEU) of continuing pharmacy education (UAN: JA0006201-9999-18-125-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Meir Kryger, MD; Steven Plenzer, MD; Russell Rosenberg, PhD,

Kish Woodward, Atlanta Progressive CME; Donna Brophy, Jennifer Browne, Molly Duda, Jennifer Ilcyn, Michael Kearney, NACCME.

Independent Clinical Reviewer: Kyle R. Copeland, PharmD; Heidi Riney, MD


Financial Disclosure and Conflicts of Interest

Dr. Kryger: Research Grant Participant - Flamel, Jazz Pharmaceuticals

Dr. Rosenberg: Research Grant Participant - Eisai, Jazz Pharmaceuticals, Vanda Pharmaceuticals

Dr. Plenzler, Ms. Brophy, Ms. Browne, Ms. Duda, Ms. Ilcyn, Mr. Kearney and Ms. Woodward have disclosed no relevant financial relationships with any commercial interests.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.